SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot.

Achtnichts, Lutz; Ovchinnikov, Arkady; Jakopp, Barbara; Oberle, Michael; Nedeltchev, Krassen; Fux, Christoph Andreas; Sellner, Johann; Findling, Oliver (2022). SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot. Vaccines, 10(2) MDPI 10.3390/vaccines10020341

[img]
Preview
Text
vaccines-10-00341-v2.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (472kB) | Preview

Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1PR-modulator treated people with MS (pwMS) and insufficient IgG responses after the standard immunization scheme. Eight pwMS that were treated with fingolimod received a third homologous SARS-CoV-2 mRNA vaccine dose, either the Moderna's mRNA-1273 or Pfizer-BioNTech's BNT162b2 vaccine. We quantified the serum levels of IgG antibodies against the receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered protective. After the third vaccination, we found clinically relevant IgG titers in four out of eight individuals (50%). We conclude that the humoral immune response may reach protective levels after the third preferred dose of the homologous SARS-CoV-2 mRNA vaccine. Vaccine shots in S1PR-modulator treated pwMS ahead of schedule may be a strategy to overcome insufficient humoral immune responses following the standard vaccination scheme.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Nedeltchev, Krassen

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2076-393X

Publisher:

MDPI

Language:

English

Submitter:

Pubmed Import

Date Deposited:

01 Mar 2022 12:29

Last Modified:

05 Dec 2022 16:11

Publisher DOI:

10.3390/vaccines10020341

PubMed ID:

35214799

Uncontrolled Keywords:

COVID-19 S1PR-modulator SARS-CoV-2 fingolimod humoral immune response vaccination

BORIS DOI:

10.48350/166125

URI:

https://boris.unibe.ch/id/eprint/166125

Actions (login required)

Edit item Edit item
Provide Feedback